Nialamide

This classification denotes a monoamine oxidase inhibitor with the molecular formula C16H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2Q0RYM725, chemically known as 4-pyridinecarboxylic acid, 2-(3-oxo-3-((phenylmethyl)amino)propyl)hydrazide (9ci) but generally known as nialamide, which bears US NIH Compound Identifier 4472. European Medicines Agency schedules Nialamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09217MIG. The term NIALAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules nialamide in its Anatomical Therapeutic Chemical (ATC) Classification. NIALAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nialamide under HS 29333999 and SITC 51574. As of Q4 2014, NIALAMIDE remains the US FDA Preferred Term for this commodity. Nialamide bears US NLM identifiers UMLS ID C0027999 and NCI Concept Code C80970. SMILES: O=C(NCc1ccccc1)CCNNC(=O)c1ccncc1.